Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Krackhardt F. | - |
dc.contributor.author | Kočka V. | - |
dc.contributor.author | Waliszewski M. | - |
dc.contributor.author | Toušek P. | - |
dc.contributor.author | Janek B. | - |
dc.contributor.author | Trenčan M. | - |
dc.contributor.author | Krajči P. | - |
dc.contributor.author | Lozano F. | - |
dc.contributor.author | Roman K.G.-S. | - |
dc.contributor.author | Otaegui I. | - |
dc.contributor.author | Del Blanco B.G. | - |
dc.contributor.author | Del Olmo V.V. | - |
dc.contributor.author | Nofrerías E.F. | - |
dc.contributor.author | Wachowiak L. | - |
dc.contributor.author | Heang T.M. | - |
dc.contributor.author | Ahn T.H. | - |
dc.contributor.author | Jeong M.H. | - |
dc.contributor.author | Jung B.-C. | - |
dc.contributor.author | Han K.-R. | - |
dc.contributor.author | Piot C. | - |
dc.contributor.author | Sebagh L. | - |
dc.contributor.author | Rischner J. | - |
dc.contributor.author | Pansieri M. | - |
dc.contributor.author | Leschke M. | - |
dc.contributor.author | Rosa S.D. | - |
dc.date.available | 2020-04-06T06:43:33Z | - |
dc.date.created | 2020-04-02 | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/26321 | - |
dc.description.abstract | Stent designs with ultrathin struts may further increase the procedural success of challenging lesion subsets. The objective of this study was to assess the safety and efficacy of ultrathin strut, polymer-free sirolimus eluting stent (PF-SES) implantations in a large scale, unselected patient population.Adult patients underwent percutaneous coronary interventions (PCI) with a thin-strut PF-SES. Data from two all-comers observational studies having the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled. The accumulated target lesion revascularization (TLR) rate at 9-12 months was the primary endpoint. All dual antiplatelet therapy strategies according to the applicable guidelines were permissible.In total, 7243 patients were prospectively enrolled for PCI with PF-SES in stable coronary artery disease or acute coronary syndrome (ACS). Major risk factors in the overall cohort were diabetes (37.3%), ST elevation myocardial infarction (18.1%) and non-ST myocardial infarction (24.6%). The follow-up rate was 88.6% in the overall population. The TLR rate in the overall cohort was 2.2% whereas definite/probable stent thrombosis (ST) occurred in 0.7%. In patients with in-stent restenosis lesions, the major adverse cardiac events rate was 6.4% whereas the corresponding rate for isolated left main coronary artery (LMCA) disease was highest with 6.7% followed by patients with culprit lesions in vein bypasses (VB, 7.1%). The mortality rate in patients treated in VB lesions was highest with 5.4%, followed by the isolated LMCA subgroup (3.4%) and ACS (2.6%).PCI with PF-SES in an unselected patient population, is associated with low clinical event and ST rates. Furthermore, PF-SES angioplasty in niche indications demonstrated favorable safety and efficacy outcomes with high procedural success rates. © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Lippincott Williams and Wilkins | - |
dc.relation.isPartOf | Medicine (United States) | - |
dc.title | Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000525864900016 | - |
dc.identifier.doi | 10.1097/MD.0000000000019119 | - |
dc.identifier.bibliographicCitation | Medicine (United States), v.99, no.8 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85079749701 | - |
dc.citation.title | Medicine (United States) | - |
dc.citation.volume | 99 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Ahn T.H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | in-stent restenosis | - |
dc.subject.keywordAuthor | MACE left main coronary artery | - |
dc.subject.keywordAuthor | polymer-free | - |
dc.subject.keywordAuthor | real-world patients | - |
dc.subject.keywordAuthor | sirolimus | - |
dc.subject.keywordAuthor | TLR | - |
dc.subject.keywordAuthor | unselected patients | - |
dc.subject.keywordAuthor | venous bypass | - |
dc.subject.keywordPlus | acetylsalicylic acid | - |
dc.subject.keywordPlus | anticoagulant agent | - |
dc.subject.keywordPlus | antithrombocytic agent | - |
dc.subject.keywordPlus | antivitamin K | - |
dc.subject.keywordPlus | clopidogrel | - |
dc.subject.keywordPlus | heparin | - |
dc.subject.keywordPlus | prasugrel | - |
dc.subject.keywordPlus | ticagrelor | - |
dc.subject.keywordPlus | antiinfective agent | - |
dc.subject.keywordPlus | polymer | - |
dc.subject.keywordPlus | rapamycin | - |
dc.subject.keywordPlus | acute coronary syndrome | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | all cause mortality | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | bleeding | - |
dc.subject.keywordPlus | cardiovascular mortality | - |
dc.subject.keywordPlus | cause of death | - |
dc.subject.keywordPlus | clinical outcome | - |
dc.subject.keywordPlus | clinical practice | - |
dc.subject.keywordPlus | cohort analysis | - |
dc.subject.keywordPlus | comparative study | - |
dc.subject.keywordPlus | controlled clinical trial | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | coronary artery disease | - |
dc.subject.keywordPlus | coronary stenting | - |
dc.subject.keywordPlus | device safety | - |
dc.subject.keywordPlus | diabetes mellitus | - |
dc.subject.keywordPlus | dual antiplatelet therapy | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | femoral artery | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | in-stent restenosis | - |
dc.subject.keywordPlus | left coronary artery | - |
dc.subject.keywordPlus | major adverse cardiac event | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | non ST segment elevation myocardial infarction | - |
dc.subject.keywordPlus | observational study | - |
dc.subject.keywordPlus | percutaneous coronary intervention | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordPlus | radial artery | - |
dc.subject.keywordPlus | ST segment elevation myocardial infarction | - |
dc.subject.keywordPlus | stent thrombosis | - |
dc.subject.keywordPlus | survival analysis | - |
dc.subject.keywordPlus | target lesion revascularization | - |
dc.subject.keywordPlus | therapy effect | - |
dc.subject.keywordPlus | vascular access | - |
dc.subject.keywordPlus | vein bypass | - |
dc.subject.keywordPlus | vein graft | - |
dc.subject.keywordPlus | acute coronary syndrome | - |
dc.subject.keywordPlus | adverse device effect | - |
dc.subject.keywordPlus | biodegradable implant | - |
dc.subject.keywordPlus | blood vessel transplantation | - |
dc.subject.keywordPlus | clinical practice | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | complication | - |
dc.subject.keywordPlus | coronary artery disease | - |
dc.subject.keywordPlus | devices | - |
dc.subject.keywordPlus | diabetes mellitus | - |
dc.subject.keywordPlus | drug eluting stent | - |
dc.subject.keywordPlus | graft occlusion | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | mortality | - |
dc.subject.keywordPlus | non ST segment elevation myocardial infarction | - |
dc.subject.keywordPlus | procedures | - |
dc.subject.keywordPlus | prosthesis design | - |
dc.subject.keywordPlus | risk factor | - |
dc.subject.keywordPlus | ST segment elevation myocardial infarction | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | Absorbable Implants | - |
dc.subject.keywordPlus | Acute Coronary Syndrome | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Anti-Bacterial Agents | - |
dc.subject.keywordPlus | Blood Vessel Prosthesis Implantation | - |
dc.subject.keywordPlus | Coronary Artery Disease | - |
dc.subject.keywordPlus | Diabetes Mellitus | - |
dc.subject.keywordPlus | Drug-Eluting Stents | - |
dc.subject.keywordPlus | Graft Occlusion, Vascular | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Non-ST Elevated Myocardial Infarction | - |
dc.subject.keywordPlus | Percutaneous Coronary Intervention | - |
dc.subject.keywordPlus | Polymers | - |
dc.subject.keywordPlus | Practice Patterns, Physicians&apos | - |
dc.subject.keywordPlus | - | |
dc.subject.keywordPlus | Prospective Studies | - |
dc.subject.keywordPlus | Prosthesis Design | - |
dc.subject.keywordPlus | Risk Factors | - |
dc.subject.keywordPlus | Sirolimus | - |
dc.subject.keywordPlus | ST Elevation Myocardial Infarction | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.